Carboplatin

"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An organoplatinum compound that possesses antineoplastic activity.

Descriptor ID

D016190

MeSH Number(s)

D02.691.800.338

Concept/Terms

Below are MeSH descriptors whose meaning is more general than "Carboplatin".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Organometallic Compounds [D02.691]
Organoplatinum Compounds [D02.691.800]
Carboplatin [D02.691.800.338]

Below are MeSH descriptors whose meaning is related to "Carboplatin".

Below are MeSH descriptors whose meaning is more specific than "Carboplatin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carboplatin" by people in Harvard Catalyst Profiles by year, and whether "Carboplatin" was a major or minor topic of these publication.

Bar chart showing 375 publications over 30 distinct years, with a maximum of 26 publications in 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1989	0	2	2
1990	1	2	3
1991	0	5	5
1992	1	3	4
1993	2	3	5
1994	1	6	7
1995	3	6	9
1996	2	6	8
1997	1	6	7
1998	2	4	6
1999	3	6	9
2000	0	5	5
2001	2	9	11
2002	2	5	7
2003	0	12	12
2004	1	6	7
2005	2	14	16
2006	6	17	23
2007	4	6	10
2008	4	21	25
2009	4	16	20
2010	3	20	23
2011	3	21	24
2012	5	21	26
2013	5	15	20
2014	4	16	20
2015	8	16	24
2016	5	14	19
2017	5	9	14
2018	1	3	4

Below are the most recent publications written about "Carboplatin" by people in Profiles.

Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52.

View in: PubMed
Shah R, Xia C, Krailo M, Amatruda JF, Arul SG, Billmire DF, Brady WE, Covens A, Gershenson DM, Hale JP, Hurteau J, Murray MJ, Nicholson JC, Olson TA, Pashankar F, Rodriguez-Galindo C, Shaikh F, Stark D, Frazier AL, Stoneham S. Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults? Gynecol Oncol. 2018 08; 150(2):253-260.

View in: PubMed
Amiri M, Basiri M, Eskandary H, Akbarnejad Z, Esmaeeli M, Masoumi-Ardakani Y, Ahmadi-Zeidabadi M. Cytotoxicity of carboplatin on human glioblastoma cells is reduced by the concomitant exposure to an extremely low-frequency electromagnetic field (50 Hz, 70 G). Electromagn Biol Med. 2018; 37(3):138-145.

View in: PubMed
Yamaguchi M, Suzuki R, Kim SJ, Ko YH, Oguchi M, Asano N, Miyazaki K, Terui Y, Kubota N, Maeda T, Kobayashi Y, Amaki J, Soejima T, Saito B, Shimoda E, Fukuhara N, Tsukamoto N, Shimada K, Choi I, Utsumi T, Ejima Y, Kim WS, Katayama N. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. Cancer Sci. 2018 Jun; 109(6):2056-2062.

View in: PubMed
Khandekar MJ, Banks AS, Laznik-Bogoslavski D, White JP, Choi JH, Kazak L, Lo JC, Cohen P, Wong KK, Kamenecka TM, Griffin PR, Spiegelman BM. Noncanonical agonist PPAR? ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. Proc Natl Acad Sci U S A. 2018 01 16; 115(3):561-566.

View in: PubMed
Kim ES, Baran AM, Mondo EL, Rodgers TD, Nielsen GC, Dougherty DW, Pandya KJ, Rich DQ, van Wijngaarden E. Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. PLoS One. 2017; 12(12):e0189410.

View in: PubMed
Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11).

View in: PubMed
Inoue M, Maeda H, Takeuchi Y, Fukuhara K, Shintani Y, Funakoshi Y, Funaki S, Nojiri T, Kusu T, Kusumoto H, Kimura T, Okumura M. Collagen gel droplet-embedded culture drug sensitivity test for adjuvant chemotherapy after complete resection of non-small-cell lung cancer. Surg Today. 2018 Apr; 48(4):380-387.

View in: PubMed
Paulino E, Nogueira Rodrigues A, Strasser-Weippl K, St Louis J, Bukowski A, Goss PE. Barriers to Primary Debulking Surgery for Advanced Ovarian Cancer in Latin America. Int J Gynecol Cancer. 2017 10; 27(8):1645-1649.

View in: PubMed
Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10; 35(32):3662-3670.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

J Clin Oncol
Clin Cancer Res
Gynecol Oncol
Cancer
Ann Oncol
Pediatr Blood Cancer
Int J Radiat Oncol Biol Phys
Cancer Chemother Pharmacol
Am J Clin Oncol
J Allergy Clin Immunol Pract